Clinical Trials Logo

Advanced Multiple Myeloma clinical trials

View clinical trials related to Advanced Multiple Myeloma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02092922 Completed - Clinical trials for Advanced Multiple Myeloma

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study. Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.

NCT ID: NCT01989325 Completed - Clinical trials for Advanced Multiple Myeloma

A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.